Symbols / MGNX $3.18 +3.58% MacroGenics, Inc.

Healthcare • Biotechnology • United States • NMS
MGNX Chart
About

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 202.11M
Enterprise Value 41.97M Income -74.62M Sales 149.50M
Book/sh 0.88 Cash/sh 2.99 Dividend Yield —
Payout 0.00% Employees 293 IPO —
P/E — Forward P/E -3.28 PEG —
P/S 1.35 P/B 3.62 P/C —
EV/EBITDA -0.64 EV/Sales 0.28 Quick Ratio 4.71
Current Ratio 5.10 Debt/Eq 66.13 LT Debt/Eq —
EPS (ttm) -1.18 EPS next Y -0.97 EPS Growth —
Revenue Growth 113.00% Earnings 2026-05-07 ROA -17.56%
ROE -86.94% ROIC — Gross Margin -22.53%
Oper. Margin -29.34% Profit Margin -49.91% Shs Outstand 63.56M
Shs Float 55.59M Short Float 7.68% Short Ratio 2.54
Short Interest — 52W High 3.54 52W Low 0.99
Beta 1.10 Avg Volume 1.09M Volume 1.04M
Target Price $3.60 Recom None Prev Close $3.07
Price $3.18 Change 3.58%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.60
Mean price target
2. Current target
$3.18
Latest analyst target
3. DCF / Fair value
$-16.49
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.18
Low
$2.00
High
$5.00
Mean
$3.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-10 main Barclays Overweight → Overweight $4
2025-11-03 reit HC Wainwright & Co. Neutral → Neutral $2
2025-08-15 main Leerink Partners Outperform → Outperform $5
2025-05-20 main B. Riley Securities Neutral → Neutral $3
2025-05-14 main Stifel Hold → Hold $5
2025-05-14 main Barclays Overweight → Overweight $3
2025-03-25 main HC Wainwright & Co. Neutral → Neutral $2
2024-11-07 down JMP Securities Market Outperform → Market Perform —
2024-11-06 reit HC Wainwright & Co. Neutral → Neutral $4
2024-09-18 reit HC Wainwright & Co. Neutral → Neutral $4
2024-08-21 reit HC Wainwright & Co. Neutral → Neutral $4
2024-08-15 main Citigroup Buy → Buy $14
2024-08-07 main BMO Capital Market Perform → Market Perform $5
2024-08-01 down BTIG Buy → Neutral —
2024-08-01 reit HC Wainwright & Co. Neutral → Neutral $4
2024-07-31 main JMP Securities Market Outperform → Market Outperform $8
2024-07-31 main Barclays Overweight → Overweight $8
2024-07-31 down Guggenheim Buy → Neutral —
2024-07-31 down B. Riley Securities Buy → Neutral $5
2024-07-29 main Barclays Overweight → Overweight $9
News
RSS: Latest MGNX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-13 BONVINI EZIO Officer — 16,665 — —
2026-02-13 RISSER ERIC BLASIUS Chief Executive Officer — 16,665 — —
2026-02-13 SPITZNAGEL THOMAS Officer — 13,332 — —
2026-02-13 PETERS JEFFREY STUART General Counsel — 13,332 — —
2026-02-13 SMITH BETH ANN Officer and Treasurer — 1,095 — —
2026-02-13 KARRELS JAMES Chief Financial Officer — 14,999 — —
2026-02-13 KOENIG SCOTT Director — 21,165 — —
2026-02-06 BONVINI EZIO Officer — 18,167 — —
2026-02-06 RISSER ERIC BLASIUS Chief Executive Officer — 17,834 — —
2026-02-06 SPITZNAGEL THOMAS Officer — 15,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
149.50
-0.31%
149.96
+155.26%
58.75
-60.84%
150.02
Operating Revenue
149.50
-0.31%
149.96
+155.26%
58.75
-60.84%
150.02
Cost Of Revenue
36.01
+192.78%
12.30
+49.59%
8.22
+11.35%
7.38
Reconciled Cost Of Revenue
36.01
+192.78%
12.30
+49.59%
8.22
+11.35%
7.38
Gross Profit
113.49
-17.56%
137.66
+172.45%
50.53
-64.58%
142.63
Operating Expense
186.33
-24.94%
248.24
+13.47%
218.77
-17.15%
264.05
Research And Development
147.17
-16.94%
177.19
+6.37%
166.58
-19.54%
207.03
Selling General And Administration
39.16
-44.88%
71.05
+36.14%
52.19
-11.47%
58.95
Other Operating Expenses
—
-1.62
-4.31%
-1.56
+19.08%
-1.92
Total Expenses
222.34
-14.66%
260.54
+14.78%
226.99
-16.37%
271.44
Operating Income
-72.84
+34.13%
-110.58
+34.28%
-168.24
-38.57%
-121.42
Total Operating Income As Reported
-72.84
+34.13%
-110.58
+34.28%
-168.24
-38.57%
-121.42
EBITDA
-59.61
-3.91%
-57.37
-2944.17%
2.02
+101.87%
-107.89
Normalized EBITDA
-59.61
+36.32%
-93.62
+37.13%
-148.91
-38.02%
-107.89
Reconciled Depreciation
7.17
-4.88%
7.54
-21.82%
9.64
-18.71%
11.87
EBIT
-66.78
-2.89%
-64.91
-750.90%
-7.63
+93.63%
-119.76
Total Unusual Items
0.00
-100.00%
36.25
-75.98%
150.93
0.00
Total Unusual Items Excluding Goodwill
0.00
-100.00%
36.25
-75.98%
150.93
0.00
Special Income Charges
0.00
-100.00%
36.25
-75.98%
150.93
0.00
Net Income
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Pretax Income
-75.29
-14.04%
-66.02
-628.88%
-9.06
+92.44%
-119.76
Net Non Operating Interest Income Expense
-2.45
-129.51%
8.31
+0.61%
8.26
+397.35%
1.66
Interest Expense Non Operating
8.51
+663.05%
1.11
-22.03%
1.43
0.00
Net Interest Income
-2.45
-129.51%
8.31
+0.61%
8.26
+397.35%
1.66
Interest Expense
8.51
+663.05%
1.11
-22.03%
1.43
0.00
Interest Income Non Operating
6.06
-35.71%
9.42
-2.74%
9.69
+483.49%
1.66
Interest Income
6.06
-35.71%
9.42
-2.74%
9.69
+483.49%
1.66
Other Income Expense
—
36.25
-75.98%
150.93
+8992.17%
1.66
Other Non Operating Income Expenses
—
—
—
1.66
Gain On Sale Of Business
0.00
-100.00%
36.25
-75.98%
150.93
0.00
Tax Provision
-0.67
-171.19%
0.94
0.00
0.00
Tax Rate For Calcs
0.00
-95.75%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
7.61
0.00
0.00
Net Income Including Noncontrolling Interests
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Net Income From Continuing Operation Net Minority Interest
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Net Income From Continuing And Discontinued Operation
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Net Income Continuous Operations
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Normalized Income
-74.62
+21.95%
-95.60
+40.24%
-159.99
-33.59%
-119.76
Net Income Common Stockholders
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Diluted EPS
—
-1.07
-613.33%
-0.15
+92.31%
-1.95
Basic EPS
—
-1.07
-613.33%
-0.15
+92.31%
-1.95
Basic Average Shares
—
62.62
+1.12%
61.93
+0.81%
61.43
Diluted Average Shares
—
62.62
+1.12%
61.93
+0.81%
61.43
Diluted NI Availto Com Stockholders
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Line Item Trend 2023-12-31
Total Assets
298.42
Current Assets
251.34
Cash Cash Equivalents And Short Term Investments
229.81
Cash And Cash Equivalents
100.96
Other Short Term Investments
128.85
Receivables
10.37
Accounts Receivable
10.37
Inventory
1.22
Raw Materials
—
Work In Process
0.26
Finished Goods
0.96
Prepaid Assets
—
Other Current Assets
9.95
Total Non Current Assets
47.08
Net PPE
45.69
Gross PPE
134.09
Accumulated Depreciation
-88.39
Properties
0.00
Machinery Furniture Equipment
14.06
Construction In Progress
1.11
Other Properties
70.30
Leases
48.62
Other Non Current Assets
1.39
Total Liabilities Net Minority Interest
145.81
Current Liabilities
56.11
Payables And Accrued Expenses
30.68
Payables
6.44
Accounts Payable
6.44
Current Accrued Expenses
24.24
Current Debt And Capital Lease Obligation
3.77
Current Capital Lease Obligation
3.77
Current Deferred Liabilities
21.65
Current Deferred Revenue
21.65
Total Non Current Liabilities Net Minority Interest
89.70
Long Term Debt And Capital Lease Obligation
30.20
Long Term Capital Lease Obligation
30.20
Non Current Deferred Liabilities
59.24
Non Current Deferred Revenue
59.24
Other Non Current Liabilities
0.26
Stockholders Equity
152.61
Common Stock Equity
152.61
Capital Stock
0.62
Common Stock
0.62
Share Issued
62.07
Ordinary Shares Number
62.07
Treasury Shares Number
0.00
Additional Paid In Capital
1,254.75
Retained Earnings
-1,102.75
Gains Losses Not Affecting Retained Earnings
-0.01
Other Equity Adjustments
-0.01
Total Equity Gross Minority Interest
152.61
Total Capitalization
152.61
Working Capital
195.23
Invested Capital
152.61
Total Debt
33.97
Capital Lease Obligations
33.97
Net Tangible Assets
152.61
Tangible Book Value
152.61
Other Inventories
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-81.04
-18.53%
-68.37
+12.57%
-78.20
+10.07%
-86.96
Cash Flow From Continuing Operating Activities
-81.04
-18.53%
-68.37
+12.57%
-78.20
+10.07%
-86.96
Net Income From Continuing Operations
-74.62
-11.43%
-66.97
-639.30%
-9.06
+92.44%
-119.76
Depreciation Amortization Depletion
7.17
-4.88%
7.54
-21.82%
9.64
-18.71%
11.87
Depreciation And Amortization
7.17
-4.88%
7.54
-21.82%
9.64
-18.71%
11.87
Other Non Cash Items
2.11
+419.36%
-0.66
-112.37%
5.34
-14.16%
6.22
Stock Based Compensation
14.29
-51.47%
29.44
+60.23%
18.37
-10.10%
20.44
Operating Gains Losses
-0.01
+99.97%
-36.31
+75.93%
-150.82
—
Gain Loss On Investment Securities
—
—
-150.93
—
Change In Working Capital
-28.33
-2135.27%
1.39
-97.39%
53.32
+969.76%
-6.13
Change In Receivables
-9.06
-249.60%
6.06
-86.79%
45.85
+200.04%
-45.84
Changes In Account Receivables
-9.06
-249.60%
6.06
-86.79%
45.85
+200.04%
-45.84
Change In Inventory
-7.91
-261.52%
-2.19
-1051.30%
0.23
+318.18%
0.06
Change In Prepaid Assets
2.77
+276.71%
-1.57
-828.84%
0.21
-98.05%
11.01
Change In Payables And Accrued Expense
-7.11
-304.84%
3.47
+198.05%
-3.54
+77.15%
-15.50
Change In Accrued Expense
-6.83
-236.60%
5.00
+203.73%
-4.82
-3.99%
-4.64
Change In Payable
-0.28
+81.70%
-1.53
-219.44%
1.28
+111.80%
-10.86
Change In Account Payable
-0.28
+81.70%
-1.53
-219.44%
1.28
+111.80%
-10.86
Change In Other Working Capital
-5.40
+43.68%
-9.58
-183.93%
11.42
-67.16%
34.78
Change In Other Current Assets
—
—
-0.01
+99.95%
-14.04
Change In Other Current Liabilities
-1.61
-131.06%
5.20
+703.95%
-0.86
-109.19%
9.36
Investing Cash Flow
-114.10
-176.42%
149.30
+286.43%
-80.08
-213.25%
70.72
Cash Flow From Continuing Investing Activities
-114.10
-176.42%
149.30
+286.43%
-80.08
-213.25%
70.72
Net PPE Purchase And Sale
-1.90
+46.33%
-3.55
-108.59%
-1.70
+53.08%
-3.62
Purchase Of PPE
-1.91
+48.35%
-3.71
-110.09%
-1.76
+51.31%
-3.62
Sale Of PPE
0.01
-93.13%
0.16
+150.00%
0.06
0.00
Capital Expenditure
-1.91
+48.35%
-3.71
-110.09%
-1.76
+51.31%
-3.62
Net Investment Purchase And Sale
-112.19
-199.42%
112.84
+243.96%
-78.38
-205.44%
74.34
Purchase Of Investment
-208.34
-169.93%
-77.18
+67.80%
-239.68
-98.74%
-120.60
Sale Of Investment
96.14
-49.41%
190.03
+17.81%
161.30
-17.26%
194.94
Net Other Investing Changes
—
40.00
—
—
Financing Cash Flow
69.51
+7141.04%
0.96
-99.36%
150.36
+8963.35%
1.66
Cash Flow From Continuing Financing Activities
69.51
+7141.04%
0.96
-99.36%
150.36
+8963.35%
1.66
Net Common Stock Issuance
0.00
0.00
-100.00%
0.62
-43.23%
1.08
Proceeds From Stock Option Exercised
0.13
-96.24%
3.44
+521.16%
0.55
-3.66%
0.57
Net Other Financing Charges
69.39
+2903.43%
-2.48
-101.66%
149.19
—
Changes In Cash
-125.62
-253.42%
81.88
+1132.85%
-7.93
+45.64%
-14.59
Beginning Cash Position
182.84
+81.11%
100.96
-7.28%
108.88
-11.81%
123.47
End Cash Position
57.22
-68.71%
182.84
+81.11%
100.96
-7.28%
108.88
Free Cash Flow
-82.95
-15.09%
-72.08
+9.87%
-79.97
+11.72%
-90.58
Income Tax Paid Supplemental Data
—
0.94
0.00
0.00
Amortization Of Securities
-1.65
+41.35%
-2.81
+43.84%
-5.00
-1341.69%
0.40
Common Stock Issuance
0.00
0.00
-100.00%
0.62
-43.23%
1.08
Issuance Of Capital Stock
0.00
0.00
-100.00%
0.62
-43.23%
1.08
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category